TABLE 3.
Demographics of Validation Cohort Separated by IBD Treatment Groups and Controls.
| Anti-TNF-α | Glucocorticoids | Control | |
|---|---|---|---|
| N | 8 | 8 | 8 |
| Age in years (mean ± SD) | 12.38 ± 3.02 | 14.12 ± 4.88 | 13 ± 3.96 |
| Males: Females | 3:5 | 4:4 | 4:4 |
| Diagnosis Crohn’s Disease Ulcerative Colitis |
3 5 |
3 5 |
|
| Months since Diagnosis (mean ± SD) | 0.84 ± 0.84 | 9 ± 25.44 | |
| Paris Classification3 Crohn’s Disease |
|||
| Distal Ileum + Cecal disease | 0 | 1 | |
| Colonic | 1 | 2 | |
| Ileocolonic | 1 | — | |
| Ileocolonic; Upper disease proximal to Ligament of Treitza | 1 | — | |
| Ulcerative Colitis Left sided UC, Never severe |
— | 1 | |
| Extensive Colitis, Never severe | 2 | — | |
| Extensive Colitis, Ever severe | 1 | — | |
| Pancolitis, Never severe | 1 | 2 | |
| Pancolitis, Ever severe | 1 | 2 | |
| Days between pre-and post-treatment sample collection: median (mean ± SD) | 53.5 (61.3 ± 29.1) | 8.5 (15.5 ± 22.3) | |
| N with concurrent mesalamine at time of both pre- and post-treatment samples | 2 | 1 | |
| PCDAI (mean ± SD) | |||
| Pretreatment | 45 ± 13.0 | 50 ± 9.01 | |
| Post-treatment | 5 ± 8.66 | 24.17 ± 10.10 | |
| PUCAI (mean ± SD) | |||
| Pretreatment | 54 ± 22.47 | 70 ± 10.60 | |
| Post-treatment | 13 ± 10.37 | 32.5 ± 16.0 |
All IBD patients in this cohort were responders to therapy.
a13 patients with IBD were enrolled, 3 patients were treated with GCs, which were tapered, and subsequently with anti-TNF-α and included in both groups.